Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Implementing Hybrid Work Policy In January

Executive Summary

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

You may also be interested in...



Peter Marks’ Fears May Come True: White House Wants More In-Person Work

The CBER director has worried that ‘someone’ might try to end the US FDA’s hybrid work policy. Now the push against it is bipartisan.

FDA Staffing: Retirements Account For More Than One-Third Of FY2023 Departures

Combination of an aging workforce and departures that were delayed by the pandemic are taking a toll on the agency’s current staffing levels, Chief of Staff Julie Tierney says.

US FDA’s Marks Worries Someone May Stop Hybrid Work System

CBER Director Peter Marks said the FDA’s remote and in-person work system is functioning well and continues to help recruitment.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel